Physician profile
Jasjit Singh
NPI 1366744021
$2,243.91
in general payments reported to CMS, 2019-2025
24 companies · $413 in 2025
The $413 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.34 · 2020: $179 · 2021: $27.74 · 2022: $546 · 2023: $482 · 2024: $524 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,399 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,399.17 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $533.92 | 2019-2025 | Tavneos, Aranesp, Parsabiv |
| Astrazeneca Pharmaceuticals Lp | $311.94 | 2022-2024 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $265.19 | 2022-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $157.16 | 2022-2025 | |
| Travere Therapeutics, INC. | $152.93 | 2023-2025 | |
| Octapharma USA, INC. | $150.05 | 2020 | |
| Aurinia Pharma U.S., INC. | $111.88 | 2022-2024 | Lupkynis |
| Glaxosmithkline, LLC. | $68.16 | 2022-2023 | Benlysta |
| Mallinckrodt Hospital Products INC. | $65.24 | 2022-2025 | Acthar |
| Akebia Therapeutics INC | $63.60 | 2022-2025 | Vafseo |
| Ani Pharmaceuticals, INC. | $48.78 | 2024 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $48.05 | 2019-2025 | Veltassa |
| Lilly USA, LLC | $35.05 | 2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $35.01 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.50 | 2024 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $22.27 | 2022 | |
| Kyowa Kirin, INC. | $22.23 | 2023 | Crysvita |
| Alexion Pharmaceuticals, INC. | $22.00 | 2019 | |
| Shire North American Group INC | $21.69 | 2019 | |
| Amicus Therapeutics, INC. | $18.65 | 2023 | Galafold |
| Calliditas Therapeutics US INC. | $16.65 | 2023 | Tarpeyo |
| Amarin Pharma, INC. | $16.11 | 2020 | |
| Horizon Therapeutics Plc | $16.01 | 2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $12.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasjit Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.